LOS ANGELES, CA / ACCESSWIRE / November 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Verve is the subject of a MarketWatch report published on November 13, 2023. According to the report, the Company's shares "fell 40% premarket on Monday after the biotech company on Sunday released early-stage clinical trial data on its experimental gene-editing treatment for high cholesterol." The report continues, "The Verve results ‘failed to beat elevated expectations' heading into the data release, Leerink Partners analysts wrote in a note Monday."
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
SOURCE: The Schall Law Firm